when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Phase 3 Readout · news · pharmadog

← back to Phase 3 Readout

News · Phase 3 Readout

32 stories

9dBMS reports liver injury events in lung disease program, with key readout nearbiospace

17dAmgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren's studybiospace

17dRoche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nodbiospace

17dRoche’s phase 3 win tees up fight with Novartis for blockbuster kidney disease marketfiercebiotech

18dVertex aims for broad kidney disease label ahead of key readout next yearendpoints

18dAmgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 winfiercebiotech

24dSling catches $123M series C for thyroid eye disease pillbiospace

26dSummit, BioNTech, more headline WCLC with next-gen lung cancer drugsbiospace

26dDefinium says its LSD drug notched another Phase 3 win in anxiety disorderendpoints

26dAfter a brief storm of political headwinds, mRNA is back with strong momentumbiospace

29dBioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readoutfiercebiotech

Sep 9, 26GV-backed Encoded gains $275M to advance Dravet drug, scale genetic med manufacturingfiercebiotech

Sep 8, 26Pharvaris' stock jumps on pivotal success in rare genetic diseaseendpoints

Sep 3, 26Chutes & Ladders—Invivyd's chairman adds CEO role ahead of COVID readoutfiercebiotech

Sep 2, 26Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN dealsbiospace

Aug 28, 26AstraZeneca, Amgen poised to challenge Dupixent’s reign with esophagitis winbiospace

Aug 26, 26Summit, Akeso tout biliary cancer win for PD-1/VEGF in China—but details are pendingbiospace

Aug 19, 26Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goalbiospace

Aug 18, 26Amylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemiabiospace

Aug 14, 26‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discoveryfiercebiotech

Aug 6, 26Vedanta gets $60M to finish Phase 3 for C. diff microbiome therapyendpoints

Jul 30, 26Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beatfiercebiotech

Jul 29, 26‘We have what we need to grow:’ Biogen CEO happy to ease off the M&A for a whilefiercebiotech

Jul 29, 26Biotechs bring big launches and pharma rivalries into Q2 earnings periodbiospace

Jul 28, 26GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyardfiercebiotech

Jul 28, 26Atea’s hepatitis C asset matches Gilead’s Epclusa in phase 3 trialfiercebiotech

Jul 27, 26RA Capital launches rare disease company Oak Hill Bio onto Nasdaq via SPACfiercebiotech

Jul 27, 26AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidatesfiercebiotech

Jul 17, 26Insmed moves closer to $6B opportunity as PAH drug shows long-term durabilitybiospace

Jul 8, 26Satellos gives early look at Duchenne pill in adults ahead of key data in childrenendpoints

← prevpage 1 of 2next →